

Guy LAURENT - Publications 2015-2020

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Équipe EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronic diseases, intervenTions, methodology

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales *Mise à jour juin 2020*

2020

1. Camille C, Dimeglio C, Yroni A, Compaci G, Delmas E, Gauché M, **Laurent G**, Birmes P. Posttraumatic Stress Disorder Symptoms in Lymphoma Patients: A Prospective Study. *Front Psychiatry*. 2020;11:201. Published 2020 Mar 11. doi:10.3389/fpsy.2020.00201.
2. Gauthier M, Conte C, Palmaro A, Patras De Campaigno E, De Barros S, Huguet F, **Laurent G**, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population-based study in France [published online ahead of print, 2020 Feb 7]. *Fundam Clin Pharmacol*. 2020;10.1111/fcp.12544. doi:10.1111/fcp.12544.
3. Mounié M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, **Laurent G**, Savy N, Laurent Molinier L. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. *J Med Econ*. 2020;23(3):235-242. doi:10.1080/13696998.2019.1702990.
4. Vayr F, Montastruc M, Savall F, Despas F, Judic E, Basso M, Dunet C, Dalenc F, **Laurent G**, Soulat JM, Fabrice H. Work adjustments and employment among breast cancer survivors: a French prospective study. *Support Care Cancer*. 2020;28(1):185–192. doi:10.1007/s00520-019-04799-w.

2019

1. Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, Bories P, Sarry A, **Laurent G**, Récher C, Lamy S. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients. *BMC Cancer*. 2019 Sep 5;19(1):883.
2. Compaci G, Conte C, Oberic L, Ysebaert L, **Laurent G**, Despas F. Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey. *BMC Cancer*. 2019;19(1):1178. doi:10.1186/s12885-019-6337-2
3. De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, **Laurent G**, Huguet F, Herin F. The impact of chronic myeloid leukemia on employment: the French prospective study. *Ann Hematol*. 2019. 98(3):615-623.
4. Jiménez Sánchez G, Maury P, Stefancikova L, Champion O, **Laurent G**, Chateau A, Bouraleh Hoch F, Boschetti F, Denat F, Pinel S, Devy J, Porcel E, Lacombe S, Bazzi R, Roux S. Fluorescent Radiosensitizing Gold Nanoparticles. *Int J Mol Sci*. 2019 Sep 18;20(18). pii: E4618
5. Mounié M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, **Laurent G**, Savy N, Molinier L. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. *J Med Econ*. 2019;1–8. doi:10.1080/13696998.2019.1702990
6. Lamy S, **Laurent G**, Lepage B, Grosclaude P, Delpierre C. Impact of comorbidity in DBLCL: direct and indirect effects on survival through unplanned chemotherapy dose reduction. *J Intern Med*. 2019. 285(4):472-474.

7. Walburg V, Rueter M, Lamy S, Compaci G, Lapeyre-Mestre M, **Laurent G**, Despas F. Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. *Psychol Health Med*. 2019. 4:1-7.
8. Walburg V, Rueter M, Lamy S, Compaci G, Lapeyre-Mestre M, **Laurent G**, Despas F. Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. *Psychol Health Med*. 2019 Aug;24(7):781-787.
9. Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, **Laurent G**, Despas F. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia. *Ann Hematol*. 2019. 98(4):931-939

2018

1. Rioufol C, Lamy S, Conte C, Jeanneau P, Compaci G, Delpierre C, Lapeyre-Mestre M, **Laurent G**, Despas F. Non-cancer drug consumption during the early trajectory of lymphoma survivorship. *Therapie*. 2018. 73(4):307-317.

2017

1. Bertoli S, Tavitian S, Huynh A, ..., **Laurent G**, et al. Improved outcome for AML patients over the years 2000-2014. *Blood Cancer J*. 2017;7(12):635. doi:10.1038/s41408-017-0011-1.
2. Magnaval JF, **Laurent G**, Gaudré N, Fillaux J, Berry A. A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia. *Mil Med Res*. 2017;4:15. doi:10.1186/s40779-017-0124-7

2016

1. Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, **Laurent G**, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study. *BMC Health Serv Res*. 2016. 16(a):336.

2015

1. Borel C, Lamy S, Compaci G, Récher C, Jeanneau P, Nogaro JC, Bauvin E, Despas F, Delpierre C, **Laurent G**. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. *BMC Cancer*. 2015. 15(1):288.